Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Interest & Investment Income: 2020-2025

Historic Interest & Investment Income for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to $4.3 million.

  • Rhythm Pharmaceuticals' Interest & Investment Income rose 6.76% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.7 million, marking a year-over-year decrease of 1.94%. This contributed to the annual value of $14.7 million for FY2024, which is 5.49% up from last year.
  • Rhythm Pharmaceuticals' Interest & Investment Income amounted to $4.3 million in Q3 2025, which was up 33.50% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Interest & Investment Income registered a high of $4.3 million during Q3 2025, and its lowest value of $21,000 during Q2 2021.
  • Its 3-year average for Interest & Investment Income is $3.6 million, with a median of $3.5 million in 2024.
  • Per our database at Business Quant, Rhythm Pharmaceuticals' Interest & Investment Income slumped by 97.38% in 2021 and then skyrocketed by 2,169.40% in 2022.
  • Rhythm Pharmaceuticals' Interest & Investment Income (Quarterly) stood at $134,000 in 2021, then soared by 2,169.40% to $3.0 million in 2022, then climbed by 25.58% to $3.8 million in 2023, then declined by 7.96% to $3.5 million in 2024, then grew by 6.76% to $4.3 million in 2025.
  • Its Interest & Investment Income was $4.3 million in Q3 2025, compared to $3.2 million in Q2 2025 and $3.6 million in Q1 2025.